Literature DB >> 32438410

The NLRP3 inflammasome in progressive multiple sclerosis.

Atsushi Kadowaki1, Francisco J Quintana1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32438410      PMCID： PMC7241945          DOI： 10.1093/brain/awaa135

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  13 in total

1.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

Review 2.  Inflammasomes: mechanism of action, role in disease, and therapeutics.

Authors:  Haitao Guo; Justin B Callaway; Jenny P-Y Ting
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

Review 3.  Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).

Authors:  William Barclay; Mari L Shinohara
Journal:  Brain Pathol       Date:  2017-03       Impact factor: 6.508

4.  Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.

Authors:  Georgia Mandolesi; Alessandra Musella; Antonietta Gentile; Giorgio Grasselli; Nabila Haji; Helena Sepman; Diego Fresegna; Silvia Bullitta; Francesca De Vito; Gabriele Musumeci; Claudio Di Sanza; Piergiorgio Strata; Diego Centonze
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

Review 5.  Multiple Sclerosis: Mechanisms and Immunotherapy.

Authors:  Clare Baecher-Allan; Belinda J Kaskow; Howard L Weiner
Journal:  Neuron       Date:  2018-02-21       Impact factor: 17.173

Review 6.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics.

Authors:  Karen V Swanson; Meng Deng; Jenny P-Y Ting
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

7.  MAFG-driven astrocytes promote CNS inflammation.

Authors:  Michael A Wheeler; Iain C Clark; Emily C Tjon; Zhaorong Li; Stephanie E J Zandee; Charles P Couturier; Brianna R Watson; Giulia Scalisi; Sarah Alkwai; Veit Rothhammer; Assaf Rotem; John A Heyman; Shravan Thaploo; Liliana M Sanmarco; Jiannis Ragoussis; David A Weitz; Kevin Petrecca; Jeffrey R Moffitt; Burkhard Becher; Jack P Antel; Alexandre Prat; Francisco J Quintana
Journal:  Nature       Date:  2020-02-12       Impact factor: 49.962

8.  The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production.

Authors:  Deepti Verma; Eva Särndahl; Henrik Andersson; Per Eriksson; Mats Fredrikson; Jan-Ingvar Jönsson; Maria Lerm; Peter Söderkvist
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

9.  Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling.

Authors:  Vanessa Beynon; Francisco J Quintana; Howard L Weiner
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 10.  Primary-progressive multiple sclerosis.

Authors:  David H Miller; Siobhan M Leary
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182
View more
  1 in total

1.  Myeloid caspase-8 restricts RIPK3-dependent proinflammatory IL-1β production and CD4 T cell activation in autoimmune demyelination.

Authors:  Sunja Kim; Hsueh Chung Lu; Andrew J Steelman; Jianrong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-07       Impact factor: 12.779
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.